Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis

McGrane, Ian R.; VandenBerg, Amy; Munjal, Robert C

doi:10.1177/1060028017720746

Cited by 5 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we found two case reports with positive response for PBA in which DM/Q was changed to dextromethorphan cough syrup plus fluoxetine, considering fluoxetine is also a CYP2D6 inhibitor. 11,12 This treatment combination was not considered for our patient as she had presented akathisia induced by fluoxetine.…”

Section: Discussionmentioning

confidence: 99%

Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

Villeneuve

Cruz-Santiago

Masson

et al. 2020

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

An elderly woman admitted in our geriatric inpatient unit suffered from disturbing outbursts of crying and, less frequently, episodes of laughing. The patient was diagnosed with pseudobulbar affect related to a mixed neurodegenerative disorder. This condition is often underdiagnosed and undertreated, despite being relatively frequent in patients with neurodegenerative disorders. This case report describes the treatment of pseudobulbar affect in this patient. The only available treatment in Canada for this condition, antidepressants, was not effective for our patient. Dextromethorphan/quinidine is a good accepted alternative, but the combination is not marketed in Canada. To manage this problem, we used compounded quinidine capsules and dextromethorphan cough syrup. The crying of our patient improved significantly and rapidly after the initiation of this treatment. This case will help professionals to review their central role in treating this complex and disabling condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

Villeneuve

Cruz-Santiago

Masson

et al. 2020

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

show abstract

“…Two placebo-controlled trials with dextromethorphan/quinidine have shown an effective therapy for PBA in MS patients [ 261 , 262 ], and treatment with fluoxetine and DXM also produced a similar effect in women with MS [ 263 ].…”

Section: Sigma Receptor Ligands For Neurological Diseasementioning

confidence: 99%

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

Malar,

Thitilertdecha,

Ruckvongacheep

et al. 2023

CNS Drugs

View full text Add to dashboard Cite

The sigma-1 receptor is a 223 amino acid-long protein with a recently identified structure. The sigma-2 receptor is a genetically unrelated protein with a similarly shaped binding pocket and acts to influence cellular activities similar to the sigma-1 receptor. Both proteins are highly expressed in neuronal tissues. As such, they have become targets for treating neurological diseases, including Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), Rett syndrome (RS), developmental and epileptic encephalopathies (DEE), and motor neuron disease/amyotrophic lateral sclerosis (MND/ALS). In recent years, there have been many pre-clinical and clinical studies of sigma receptor (1 and 2) ligands for treating neurological disease. Drugs such as blarcamesine, dextromethorphan and pridopidine, which have sigma-1 receptor activity as part of their pharmacological profile, are effective in treating multiple aspects of several neurological diseases. Furthermore, several sigma-2 receptor ligands are under investigation, including CT1812, rivastigmine and SAS0132. This review aims to provide a current and up-to-date analysis of the current clinical and pre-clinical data of drugs with sigma receptor activities for treating neurological disease.

show abstract

“…To date, only strong CYP2D6 inhibitors have shown efficacy in combination with dextromethorphan for PBA. Two case studies showed that the combination of fluoxetine and dextromethorphan led to improvement in PBA 5,6 . The following is a case of a patient with symptoms of debilitating anxiety who was diagnosed with PBA and successfully treated with a combination of fluoxetine and dextromethorphan.…”

mentioning

confidence: 98%

Management of Pseudobulbar Affect With Fluoxetine and Dextromethorphan

Bent

Hwang

Meyer

et al. 2021

J Clin Psychopharmacol

View full text Add to dashboard Cite

Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis

Cited by 5 publications

References 4 publications

Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

Management of Pseudobulbar Affect With Fluoxetine and Dextromethorphan

Contact Info

Product

Resources

About